<DOC>
	<DOCNO>NCT02975986</DOCNO>
	<brief_summary>We test hypothesis renal uptake free ( i.e . non-esterified ) fatty acid ( FFa ) increase iuan . To accomplish goal measure renal FFa uptake FFa uptake vivo patient iuan match non-stone forming subject via single-photon emission compute tomography ( SPeCT ) /CT image . The definitive proof hypothesis rest whether increase renal FFa uptake demonstrable human iuan .</brief_summary>
	<brief_title>Renal Uptake Fatty Acids ( FFA ) Patients With Idiopathic Uric Acid Nephrolithiasis ( IUAN )</brief_title>
	<detailed_description>This cross-sectional study patient iuan match non-stone former test hypothesis renal FFa uptake increase iuan , use noninvasive 123i-labeled [ MiCRo-SYMBoL ] -methyl-p-iodo-phenyl-pentadecanoic acid ( 123i-BMiPP ) SPeCT/CT imaging , establish FFa analog approve human study . Participants place instruct controlled metabolic diet ( 30 % fat , 15 % protein , 55 % carbohydrate , 300 mg cholesterol per day , 400 mg calcium , 800mg phosphorus , 100 meq sodium , low acid ash content , 3000 cc distil water ) 5 day exclude dietary confounders ( 3 day outpatient final 2 day inpatient ) . day 4 5 , two fast blood sample collect measurement CMP , insulin , FFa two 24-h urine sample collect mineral oil analyze total volume , pH , Cr , na , K , Ca , Mg , Cl , P , uric acid , nH4+ , titratable acidity ( Ta ) , sulfate , HCo3- citrate . The morning day 6 , patient undergo dual 123i-BMiPP 99mTc-MaG3 ( 99mTc mercaptoacetyltriglycine mertiatide ) SPeCT/CT image 12 hrs fasting . 99mTc-MaG3 ( 8-10mCi ) inject intravenously flow phase standard renal scan include dynamic image 2 minute . additional 1 minute image acquire ( 2-3 minute image standard renal scan ) . acquisition stop . immediately afterward 123i-BMiPP ( 4-5mCi ) inject intravenously 1hour uptake period . 1 hour uptake dual isotope ( Tc-99m i-123 ) SPeCT/CT image kidney acquire clinical Siemens Symbia dual head SPeCT/CT system . The 99mTc-MaG3 flow image data use measure renal plasma flow,12 use Ge Xeleris renal analysis software package already installed clinical SPeCT/CT system . The 123i-BMiPP , gamma emitter half-life 13.13 hour , measure renal 123i-BMiPP ( FFa ) uptake 13 123i-BMiPP uptake correct effective renal plasma flow ( mL/min ) measure 99mTc-MaG3 , use Ge Xeleris renal analysis software package . expect finding : hypothesis correct , expect increase FFa uptake measure 123i-BMiPP SPeCT/CT correct renal effective plasma flow kidney cortex iuan patient vs. match control .</detailed_description>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>In IUAN group ( N=10 ) , include adult subject document IUAN , age &gt; 21 year , either sex , ethnicity In Control group ( N=10 ) , include volunteer history stone disease match age ( within 5 year ) , gender , ethnicity , BMI ( within 10 % ) diabetes status Contraindications SPECT/CT , pregnancy , breastfeeding , chronic renal disease ( eGFR &lt; 60 ml/min/1.73m2 ) , proteinuria , genetic disease kidney , inborn defect lipid metabolism , alcohol abuse , liver disease ( patient highly elevated total bilirubin , elevate liver enzymes AST , ALT alkaline phosphatase establish liver disease ) , anemia , pharmacological treatment insulin insulinsensitizing drug thiazolidinediones ( TZD ) . Patients antidyslipidemic drug , alkali therapy allopurinol instruct discontinue drug 2 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>acidic , urine , nephrolithiasis , free fatty acid .</keyword>
</DOC>